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ABSTRACT 
Azaribine. asap~ nmidine analog, blocks the decarboxyla:.e conversion of orotidylic acid to 
uridine monophosphate with a resultant excretion of accumulated orotic acid and orotidine 
in the urine. Patients treated with azaribine may develop transitory. severe central nervous 
system symptoms of depression. lethargy, and ataxia. These side effects are not predictable 
from oral dosage, and blood levels of the drug are very difficult to determine. All of our 
psoriatic patients treated with azaribine excreted large but variable amounts of orotic 
acid orotidinc in the urine. , pol urine ratios of orotic acid orotidine: creal mine correlated 
very well with measured 24-hr urine output of orotic acid orotidine. 
Patients with central nervous system symptoms were found to have very high urine levels 
of orotic acid orotidine. These symptoms can be prevented by monitoring the urinary orotic 
acid orotidine : creatinine ratio levels and keeping them within a range which is still 
compatible w1th successful management of the psoriatic lesions. 
Triazure (azaribine) the triacetylated oral form 
of 6-azauridine i:. an effective systemic drug for 
controlling moderate to &evere psoriasis (1). In a 
double-blind crossover study [2) conducted by us. 
the effect of azaribine in 27 patients with psoriasis 
was evaluated at a dose of 125 mg/kg/day. Clinical 
response was considered to be good to excellent in 
18 out of 21 patients on the drug, whereas 19 of the 
20 patients on the plareho showPd no improvement 
or deterioration of their skin lesions. Toxic side 
effects include a mild reversible anemia and cen-
tral nervous system (C SJ symptoms of depres-
sion, and lethargy which may progress to ataxia. 
These symptoms are not predictable from the 
oral dosage of azaribine administered. Blood and 
urine levels of azaribine and its breakdown prod-
ucts including 6-azauridine are difficult to mea-
sure. requiring the use of complicated chromato-
graphic techniques. 
Azaribine IS a nucleos1de structural analog of 
uridine [3 ). When 6-azauridine was given orally [3) 
it was poorly absorbed and the small amount that 
was absorbed was rapidly excreted in the urine, 
predominantly as 6-azauracil following cleavage of 
the ribose group. Although 6-azauridine is not 
believed to pass the blood brain barrier [3], 6-
azauracil passes the blood brain barrier easily and 
is very toxic to the central nervous system [4-6 ]. 
Ln contrast to oral 6-azauridine, repeated oral 
dosage of azaribine results in sif(Tlificantly pro-
longed blood level~ of 6-azauridine with minimal 
formation of 6-azauracil [3. 7). 
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The de novo pyrimidine pathway [3, 7, 8) for the 
conversion of orot1c acid to uridylic acid is re-
viewed in Figure l. 6-azauridme is converted to the 
monophosphorylated form, 6-azauridylic acid, by 
uri dine kinase p ). This derivative competitively 
inhibits the decarboxylase conversion of o rotidylic 
acid (OMPJ to uridylic acid, resulting in the 
accumulation of OMP and orotic acid and a 
decreased production of RNA [9) and DNA. O M P 
is excreted in the urine as orotidine. O rotic acid is 
not detected in normal tissue and only 1-2 mg are 
excreted in the urine daily in a normal subject. 
Approximately 2.5 mg of orot1dine are excreted in a 
24-hr urine [10). Orotic acid has only two known 
pathways of metabolism in humans. By a reversa l 
of reaction!> in Figure I. OMP can be reduced to 
dihydro-orotic acid and subsequently hydrolyzed 
to carbamyl aspartate. Most of the orotic acid is 
converted in the de novo pyrimidine pathway to 
uridylic acid [II). 
The following report describes the procedures 
used by us for following psoriatic patients on 
azaribine with urine orotic acid orotidine ( OA 1 
OJ/c reatinine ratios as a guideline to prevent C;-JS 
side effects. 
MATF:HIALS AND METHODS 
Se/ectwn of Patwnts 
Thirty-eight patients with untreated moderate to se-
vere psona~is wPre sPIPcted for study. The patients 
re(·ein•d no systemic or topical treatment to their skin for 
one month prwr lilt he "tudy. The patients seleded had 
no generallted sy~temtc 11lness such as anemia. renal or 
Ji, er dtsease which would contraindicate use of an 
antip~rimidine Initial exammation included histof) and 
physical exammallon, urmalysis, chest x-ray. determma· 
tiun uf CHC. SGOT, alkalmP pho~phatase. creatinine, 
and blood sugar Photographs were obtained. Women ol 
child-lu.>armg age received a pre~nancy te:.t befnre ther-
apy and dunng lrPatment at regular intervals. Most of 
the "llhJects "ere fnlluwcd ru. oUl-patients. 
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Ftt:. I: De novo pynmtdine pathway for the synthesis 
of undvlit· ot·td from orntie a<·id The decarboxvla~e block 
by 6-azaundvlic acid 1,., ,ho'"" · 
Plan of Stud\ 
T he patients were millall) begun on 1:.1.'1 mg azaribine/ 
kg/day in lnur equally d1' idcd do~e' taken a lt er meal~ 
and at bedume The 1>a t 1ent~ ''ere seen weekly and the 
time ol treatment for each ,·aried from approximntely 
4 10 week..., depending on response 10 therap~· . It was 
poss1ble to obtain I(Ond dmttal results t80 90 per(·ent 
resolution of psorillllC plaque~) withm 4- 10 weeks after 
begmnmg the rap\ 10 mcl'it patient~ At each dink visit 
the skm response wos evaluated un a grading 'cale as 
follows: Patients w1th llO \00 percent clearing of the skm 
were graded ru, excellen t : those with 60 0 pe rcPnt 
improvem ent as good; 40-60 percent resolution of the 
lesions was graded us fa1r: 10 percent improvement to no 
c hange was graded as no improvement: and progres,.,ion 
of the di~easc was graded as wnrse. The patients were al~o 
evalua ted to r the C'NS "ide effPcts of depression. faugue. 
letharJ0. and atax111. Svmptoms of nausea were also 
documented. 
The patients were told to void a nd discard thetr unnc 
a t home before <·omtng to the clinic in the a.m. Linne 
samples were collected ut each visit: l ('C nf u rinl' was sent 
to the laboratory J(Jr spot urine creatinine determination 
and 1 cc was fro1en for determmation ofOA • 0 levels. 
Oralie Actd ()rnl!dtne Drtermtnatwm 
OA · 0 determmatwn ha~ bPen renewed in detail 10 
several puhlicatton~ jiO, 121 and we have pre,·iou"l) 
shown 121 that OA + 0 ran he measured in t he unne of 
psonat1c pattenh by a modthc:auon of IU>gen< and Port -
er's 1121 spectwphotnml't ric method fnr determmmg 
urine urollc at·td level" The as"a' a, originally descrihed 
hy Adachi [I :ll 1s bnelh re' iewed here as it applies to 
azaribine therapL It 1s hased upon the principal that 
ornt 1c arid and/or orotidine reac1 with bromine water to 
form 5. fi' -dihromnbarhll uriC' acid This C'ompound is 
reduced bv a~corhic acid to barbituric acid. Harbnunc 
ac1d react!' w1th p-dimethvlaminobenzaldehyde ( Ehr-
lich 's reagent) fo rmmg a yellow color wh1ch ha!i a 
max1mum optical density <i t 480 m". Pure OA 0 
produt•e an optical dens1tv proportional to concentration. 
In the unne of an mdtvidual sec reting large amounts of 
OA • 0. the rnncl'ntrauon of OA • 0 IS high. alltm ing 
the tN' of wry ~mall mlume;; of urine. 
Before ossa\, all precipitated OA - 0 was redissolved 
by warming the bample. and the analysis was <'arried out 
at room temperature. A .05 ml aliquot was m1xcd with 
2.9fi ml ol 0.2 M pma~sium ctl rate buffer. pll 2.fi. A blank 
was pre pared lmm :1 ml of the buffer. O.!i ml of satura ted 
bromine water was added to the sample. After l min Ul 
ml of ;)'"r llRrnrbic acid in the buffer was odded. After 2 
min 2 ml ol Vi' • p-dtmethylammobenraldehyde in 
~-propanol were added. and after 90 mm the opllt'al 
denstly at IRO m" wa~ dPtermmed in a Heckm11n sphec-
t m photnmt'ler. A standard curve was determined for 
known 'alup,. ol orotic acid added to control urines and 
the concentra!lon!-. of orotic acid in micrograms/ millilitl'r 
lor ~pC'cimens under consideration "ere taken from the 
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standa rd cur.·P. ThP t•nnt•entration of OA t 0 in the 
urine sample I I' Will II wa-. dh tded h\· the unne creal inine 
(mj(/mll resultmg in a ratm !'X t>re~sed a.' ~Jidmg. Azan-
hine I 1 R m~l. 6-;uatmdtnl' 1!1 mgl. 6-a1auridylic acid t:l 
mgl and uridine (:i mgl dtd nut I( I\ l' culor in the a~"a' 
OA ., 0 expressed as a ratio over creatinine on the 
sa me spe<·i men correlated well with the amount of 
OA ... 0 excreted in the urine in 24 hr. This 
correlation is shown in Figure 2. 
The dail~ response cur\'e for excretion of OA t 0 
in any mdi\'idual patient on azaribine is shown in 
Figure :t The OA + 0 ratios from mo. t of our 
pat ienh peaked in the first 4 hr after beginning 
azaribine and then 11uct uated at a lower le,·el m·er 
the following weeks of treatment. This excretion 
RESll.TS 
inre it was difficult and tedious for out -patients 
to collect and sa,·e 24-hr urine »pecimen~. we 
determined that a random urine determination fo r 
TAHLE I 
Azanbine therap.\ for psoria.~is lomite al·td • urotidine/crealtntne ratw.~) 
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pattern in psoriatics agrees wtth results reported 
by Falon et al [141 on leukemic patients who were 
given 6-azauridine intra\·enously. 
The subsequent results of the urine OA + 0 
determinations in this ~tudy were all from samples 
taken at least 5 days alter a patient was begun on 
azaribine therapy. Therefore, the OA + 0 ratios 
analayzed would not be innuenced by the early 
48-hr peak. The results of the OA 0 creatinine 
ratios for all of our pat tents treated with azaribine 
are summarized in Tables I, Il, and Figure 4. In 
Table I are listed all of the patients, number of 
weeks on the drug, dosage, ratio range, number of 
urine OA +- 0 creatinine determinattons, the 
number and value of each ratio over 600, and 
symptom~. The severe C S symptoms as noted 
were at the times of the elevated ratios only 
although the dosage range for both the symp-
tomatic and asymptomatic patient:-. was stmilar. 
Table II summarizes the number of urine determi-
nations. ratio ranges, and their correlation with 
definite severe CNS symptoms. Figure 4 represents 
a histogram summary of the urine ratio determina-
tions and their relationship to severe c.:-.;s symp-
tom:-.. 
Analysis of the~e data has shown a statistically 
signtlicant difference tn the tnctdence of c.:-.;s 
symptoms between the patients with ratios above 
or below 600. Usmg Fisher's Exact Test for tables. 
the p \'alue is < 0.001. Patients who had OA + 0 
TAHLE II 
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creatinine ratios that ranged between 250 and 600 
had minimal to no CNS symptoms with good 
clearing of their psoriatic plaques. Howe\·er when 
a patient's OA 1 0 ratio began to go above 600, he 
would begin to experience marked mental symp-
toms of depression, fatigue and/or lethargy. Three 
patients who had ratios O\·er 600 also had symp-
toms of nausea and/or emesis. We observed that if 
the daily dosage of azaribine was lowered by 25 40 
percent in a patient who began to develop C. S 
symptoms. there was a rapid decrease to absence of 
the CNS symptoms within 24 48 hr and a corre-
sponding drop in the OA "" 0 ratio . Three patients 
from this group and three from another study who 
were followed with OA ... 0 ratios below 200 had 
poor clinical responses . The ratio was also an aid in 
determinmg whether a patient was actually taking 
his full prescribed daily dosage of azaribine. A 
patient who misses doses of the drug will have very 
low ratios (Table I). Most of our patients had 80 90 
percent resolution of their psoriattc lesions at a 
dosage level of azarihine that would keep their 
average ratio between 200 and 600 during the 
course of treatment. This ratio level corresponded 
to a dosage range of 3.5- 12.5 gm of azaribine per 
day in our patient group. The average dosage for 
satisfactory therapy with minimal CNS symptoms 
was 7.5 gm/day. Five of our patientR who had very 
severe depre::.sion and/or ataxia had very high 
ratios. 
VVithout the use of the OA t 0 /creatinme ratio 
we found it difficult to adjust and monitor the 
proper dosage of azaribine in treating our psoriatic 
patients. The ratio was helpful tn determinmg 
when a patient was at a safe dosage level with 
regard to preventmg CNS symptoms. 
COMME!I.TS 
There ts a rare genetic disorder of pyrtmidine 
metabolism in humans characterized by retarded 
growth and development, hypochromic anemia, 
and excessive urinary excretion of orotic acid 1111. 
The anemia is unresponsive to the usual forms of 
therapy. This genetic disease is known as heredi-
tary orotic aciduria 181 and less than 10 cases have 
been reported. It represents the only specific ge· 
netic disorder of pyrimidine nucleotide synthesis so 
far elucidated in man. Studies of hemic cells, liver 
homogenates, and fibrobla~ts from these children 
have demonstrated reduced activities of both oro-
tidylic pyrophosphorylase and orotidylic decar-
boxylase. These enzymes catalyze the conver::.ion 
of orotic acid to uridylic acid. Reduced levels or 
inhibition of these enzymes result in excretion of 
high le\·els of orotic acid in the unne. Administra-
tion of 6-azauridine in man produces a somewhat 
analogous ~ituation. All of our patients on azari-
bine ( 125 mg/kg/dayl excreted large amounts (0.2 1.:~ gm) of orotic acid orotidine (OA + Ol in 
the urine in 2·1 hr. 
Azarihine is an effeetive method for controlling 
severe psoriasts. but while under treatment v. ith 
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this drug mo~t p~oriatic patientl> will experience 
moderate to . evere CN' symptoms if their daily 
dosage is too high. From our experience we believe 
that patients should be start ed on a maximum 
initial dose of 6 8 gm of azaribine per day. Most 
patients in our experience do not tolerate a higher 
initial dosage without symptoms of depression, 
fatigue. nausea and/or emesis. However, it can be 
difficult to predict from the calculated daily dos-
age of azaribine whether or not a patient will 
develop C S side effects. We have found that the 
spot unne OA t 0 creatinine ratio is an excellent 
guide to follow psoriatic patients on azaribine. By 
following the spot urine ratios we have been able to 
adjust the dosage of azaribine in our severe pso-
riatic patien ts in orde r to keep their ratios within a 
therapeutic ra nge while at the same time prevent-
ing them from developing C S side effects. 
Azarioine wa~ ktndly ouppliecl hv the Calbwchern 
Com pan) . San Diego. C'allfnrma. 
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